Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.

The full result from Eisai’s large, global phase 3 confirmatory Clarity AD clinical study of lecanemab – an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of ...

In the context of the “dual-high” power grid, the study of grid-connected inverters that enhance power quality while maintaining fault tolerance under unbalanced conditions carries significant ...